LU90097I2 - Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique - Google Patents

Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique

Info

Publication number
LU90097I2
LU90097I2 LU90097C LU90097C LU90097I2 LU 90097 I2 LU90097 I2 LU 90097I2 LU 90097 C LU90097 C LU 90097C LU 90097 C LU90097 C LU 90097C LU 90097 I2 LU90097 I2 LU 90097I2
Authority
LU
Luxembourg
Prior art keywords
ropinirole
optionally
pharmaceutically acceptable
acceptable salts
hydrochloric salt
Prior art date
Application number
LU90097C
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23776840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90097(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of LU90097I2 publication Critical patent/LU90097I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU90097C 1982-12-07 1983-11-30 Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique LU90097I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/447,564 US4452808A (en) 1982-12-07 1982-12-07 4-Aminoalkyl-2(3H)-indolones

Publications (1)

Publication Number Publication Date
LU90097I2 true LU90097I2 (fr) 1997-07-16

Family

ID=23776840

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90097C LU90097I2 (fr) 1982-12-07 1983-11-30 Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique

Country Status (27)

Country Link
US (1) US4452808A (fr)
EP (1) EP0113964B1 (fr)
JP (1) JPS59112964A (fr)
KR (1) KR910001042B1 (fr)
AU (1) AU560170B2 (fr)
BR (1) BR1100036A (fr)
CA (1) CA1208650A (fr)
CY (1) CY1497A (fr)
CZ (1) CZ398191A3 (fr)
DE (1) DE3367090D1 (fr)
DK (1) DK156514C (fr)
DZ (1) DZ587A1 (fr)
EG (1) EG16556A (fr)
ES (2) ES8600239A1 (fr)
FI (1) FI77849C (fr)
GR (1) GR79121B (fr)
HK (1) HK82089A (fr)
IE (1) IE56347B1 (fr)
IL (1) IL70311A (fr)
LU (1) LU90097I2 (fr)
NL (1) NL970005I2 (fr)
NO (2) NO160135C (fr)
NZ (1) NZ206344A (fr)
PH (1) PH22067A (fr)
PT (1) PT77739B (fr)
ZA (1) ZA839094B (fr)
ZW (1) ZW25883A1 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
US4657929A (en) * 1983-10-25 1987-04-14 Fisons Plc Compounds
US4554284A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
GB8621040D0 (en) * 1986-08-30 1986-10-08 Smith Kline French Lab Process
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
JPH07506823A (ja) * 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9526511D0 (en) * 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
ATE218548T1 (de) * 1996-08-27 2002-06-15 American Home Prod 4-aminoethoxy-indolon-derivate
ZA992670B (en) * 1998-04-13 2000-10-12 American Home Prod 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists.
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
WO2002069974A1 (fr) * 2001-03-05 2002-09-12 Andrew Holman Administration d'agents restaurateurs de sommeil
FR2821843B1 (fr) * 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
JP4630665B2 (ja) * 2002-09-13 2011-02-09 モタック・ニューロサイエンス・リミテッド ２，３−ベンゾジアゼピンによる基底核関連運動障害の治療
CA2499200A1 (fr) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Traitement de la dyskinesie
ES2237307B1 (es) 2003-10-14 2006-11-01 Urquima, S.A. Procedimiento para la preparacion de ropinirol.
WO2005074387A2 (fr) * 2003-12-30 2005-08-18 Sun Pharmaceutical Industries Limited Nouvelles formes cristallines d'hydrochlorure de 4-[2-di-n-propylamino)ethyl]-2 (3h)- indolone
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
WO2005105741A1 (fr) * 2004-02-11 2005-11-10 Sun Pharmaceutical Industries Limited Hydrochlorure de 4-[2-(di-n-propylamino)ethyl]-2(3h)-indolone sensiblement pur
WO2005080333A1 (fr) * 2004-02-19 2005-09-01 Torrent Pharmaceuticals Ltd Processus de purification de ropinirole
HRP20090054T3 (hr) * 2004-05-11 2009-03-31 EGIS Gy�gyszergy�r Nyrt Derivati piperazina alkilnih oksindola
HUP0400953A3 (en) * 2004-05-11 2008-02-28 Egis Gyogyszergyar Nyilvanosan Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
WO2006100588A1 (fr) * 2005-03-21 2006-09-28 Pfizer Limited Derives de triazole substitues utilises en tant qu'antagonistes d'oxytocine
CN100457711C (zh) * 2005-06-27 2009-02-04 上海奥博生物医药技术有限公司 2-甲基-3-硝基苯基烷基胺衍生物或其盐的制备方法
WO2007010557A2 (fr) * 2005-07-22 2007-01-25 Ind-Swift Laboratorie Limted Methode de preparation de ropinirole tres pur
EP2007721B1 (fr) 2006-03-29 2011-07-27 Alembic Limited Procédé de purification du chlorhydrate de ropinirole
KR101446813B1 (ko) * 2006-04-06 2014-10-01 뉴파쎄 인크. 도파민 연관된 상태의 치료를 위한 이식체
US20070254941A1 (en) * 2006-04-21 2007-11-01 Glenmark Pharmaceuticals Limited Subtantially pure ropinirole hydrochloride, polymorphic form of ropinirole and process for their preparation
CN100457732C (zh) * 2006-05-25 2009-02-04 药源药物化学（上海）有限公司 罗匹尼罗的制备方法
WO2008001204A2 (fr) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Compositions transdermiques de pramipexole présentant des propriétés de perméation améliorées
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
US20090076124A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ropinirole
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
WO2010023693A2 (fr) * 2008-09-01 2010-03-04 Lupin Limited Nouvelles compositions de ropinirole à libération contrôlée
CA2738414C (fr) 2008-09-29 2014-05-27 Wockhardt Research Centre Forme posologique a liberation prolongee de ropinirole
US20100130582A1 (en) * 2008-11-24 2010-05-27 Auspex Pharmaceuticals, Inc. Indolinone modulators of dopamine receptor
US9238025B2 (en) 2009-05-21 2016-01-19 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation comprising a ropinirole derivative
EP2513055A1 (fr) * 2009-12-16 2012-10-24 Pharmathen S.A. Procédé de préparation de ropinirole et de ses sels
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
CN101891641B (zh) * 2010-07-27 2015-06-10 北京华禧联合科技发展有限公司 盐酸罗匹尼罗关键中间体的稳定形态及其制备
TWI537274B (zh) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途
EP2688561B1 (fr) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
EP2776020B1 (fr) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Méthodes pour le traitement de tumeurs de la peau
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
US9585885B2 (en) 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US10961194B2 (en) 2017-06-16 2021-03-30 Zhejiang Huahai Licheng Pharmaceutical Co., Ltd. Method for purifying ropinirole hydrochloride
CN115466209A (zh) * 2022-09-29 2022-12-13 南通大学 一种罗匹尼罗环戊烷并吲哚酮杂质的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA895875A (en) * 1972-03-21 Bourdais Jacques Mercapto indole derivatives
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
JPS5840539B2 (ja) * 1976-03-31 1983-09-06 大塚製薬株式会社 α−置換アミノアルカノイルオキシインド−ル誘導体
JPS5825673B2 (ja) * 1976-03-31 1983-05-28 大塚製薬株式会社 オキシインド−ル誘導体
JPS5919537B2 (ja) * 1976-08-02 1984-05-07 大塚製薬株式会社 オキシインド−ル誘導体
US4317944A (en) * 1980-08-15 1982-03-02 General Electric Company Preparation of 2,2-bis(4-hydroxyphenyl) propane
US4314944A (en) * 1980-08-22 1982-02-09 Smithkline Corporation 4-Aminoalkyl-7-hydroxy-2(3H)-indolones

Also Published As

Publication number Publication date
DK562183A (da) 1984-06-08
PT77739A (en) 1983-12-01
CY1497A (en) 1990-02-16
NZ206344A (en) 1987-03-31
DK156514C (da) 1990-03-12
IE832866L (en) 1984-06-07
US4452808A (en) 1984-06-05
HK82089A (en) 1989-10-20
DK156514B (da) 1989-09-04
AU560170B2 (en) 1987-04-02
IL70311A (en) 1986-11-30
FI834421L (fi) 1984-06-08
ES527827A0 (es) 1985-10-01
GR79121B (fr) 1984-10-02
EP0113964A1 (fr) 1984-07-25
NL970005I1 (nl) 1997-04-01
NO1999011I1 (no) 1999-06-18
DZ587A1 (fr) 2004-09-13
DK562183D0 (da) 1983-12-06
AU2158583A (en) 1984-06-14
EP0113964B1 (fr) 1986-10-22
KR840006963A (ko) 1984-12-04
BR1100036A (pt) 2000-01-11
IE56347B1 (en) 1991-07-03
CZ398191A3 (en) 1993-02-17
FI77849C (fi) 1989-05-10
NL970005I2 (nl) 1997-10-01
NO160135B (no) 1988-12-05
EG16556A (en) 1989-01-30
ES8600239A1 (es) 1985-10-01
NO160135C (no) 1989-03-15
ZW25883A1 (en) 1984-04-18
ZA839094B (en) 1985-02-27
FI77849B (fi) 1989-01-31
IL70311A0 (en) 1984-02-29
KR910001042B1 (ko) 1991-02-21
PH22067A (en) 1988-05-20
CA1208650A (fr) 1986-07-29
JPS59112964A (ja) 1984-06-29
ES543593A0 (es) 1986-01-16
JPH0150703B2 (fr) 1989-10-31
FI834421A0 (fi) 1983-12-02
DE3367090D1 (de) 1986-11-27
PT77739B (en) 1986-03-27
ES8604143A1 (es) 1986-01-16
NO834485L (no) 1984-06-08

Similar Documents

Publication Publication Date Title
LU90593I2 (fr) Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU88809I2 (fr) Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU90426I2 (fr) Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU88746I2 (fr) Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU91372I2 (fr) Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
BE875890A (fr) Enlevement d'impuretes sous forme de parties par milliard de saumures alcalines
LU90098I2 (fr) Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
DK425583D0 (da) Fremgangsmade til fremstilling af 4'-demethyl-epipodophyllotoxin-beta-d-ethylidenglycocid og acylderivater deraf samt mellemprodukt til brug ved fremgangsmaden
LU88797I2 (fr) Raltitrexed et ses sels esters et hydrates pharmaceutiquement acceptables
LT2274B (lt) Benzimidazolo dariniu arba ju drusku gavimo budas
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
IT1197502B (it) Protesi acustica da inserire nell'orecchio
EP0278173A3 (en) Use of heterocyclic derivatives in the treatment of depressions
LU92564I2 (fr) Médocaril de ceftobiprole et les sels pharmaceutiquement acceptables qui en dérivent
FI892134A7 (fi) Kovakudoksen pintakäsittely
ES537312A0 (es) Procedimiento para la desintegracion de derivados de s-triacin en soluciones acuosas
ITRM910026A0 (it) Generatore di acqua dolce
FR2553661B1 (fr) Nouvelles microemulsions pharmaceutiquement acceptables
FR2297842A1 (fr) Procede de preparation d'olefino-sulfonates sous forme hautement concentree
DK165213C (da) Apparat til brug ved afskaering af fisks hoveder
FR2542197B1 (fr) Remede medicamenteux et prophylactique anticarie dentaire sous forme de granules